Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study

Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, Christine A. White

Research output: Contribution to journalArticlepeer-review

185 Scopus citations

Fingerprint

Dive into the research topics of 'Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds